| Value of contrast-enhanced multiphase CT in combined PET/CT protocols for oncological imaging. | |
| | |
MedLine Citation:
|
PMID: 17329683 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
To evaluate the additional value of contrast-enhanced multiphase CT in comparison with low-dose non-contrast CT in combined positron emission tomography (PET)/CT protocols for oncological imaging, we retrospectively analysed 100 patients with different malignant tumours. All patients underwent a PET/CT consisting of a multiphase CT protocol including a low-dose non-enhanced attenuation scan and an arterial and portal-venous contrast-enhanced scan followed by a whole-body PET. PET/CT studies were analysed by different categories to determine the added value of contrast-enhanced CT. The additional value was defined as new information provided by diagnostic CT and not available from the low-dose CT, resulting in change of PET/CT interpretation. The results were validated either by histopathology or by clinical-radiological follow up at > or =6 months. The clinical impact was evaluated with respect to changes in patient management. Diagnostic multiphase CT was of additional value in 52 out of 100 patients with 85 suspected lesions. In 40 out of 100 patients, no additional value could be detected. Eight patients were excluded due to inconclusive diagnosis in both methods including fusion. The analysis showed the greatest benefit of diagnostic CT in the categories localization of pathological fluorodeoxyglucose (FDG) uptake and precise tumour delineation, changing PET/CT interpretation in 42% and 31% of patients, respectively. The benefit of diagnostic CT was influenced by the tumour type demonstrating the highest impact in gastrointestinal, lung and neuroendocrine tumours. Diagnostic CT changed clinical management in 21 patients (21%). Diagnostic multiphase CT as part of the combined PET/CT protocol has the potential to provide considerable additional value in specific clinical conditions with resultant change of management in a substantial proportion of patients. |
| | |
Authors:
|
A C Pfannenberg; P Aschoff; K Brechtel; M Müller; M Klein; R Bares; C D Claussen; S M Eschmann |
Related Documents
:
|
17873133 - Limitations of ct during pet/ct. 16626793 - The impact of pet/ct in the management of recurrent ovarian cancer. 2673313 - Evaluation of intrahepatic tumour extent and prediction of resection size in liver tumo... |
Publication Detail:
|
Type: Evaluation Studies; Journal Article Date: 2007-02-28 |
Journal Detail:
|
Title: The British journal of radiology Volume: 80 ISSN: 1748-880X ISO Abbreviation: Br J Radiol Publication Date: 2007 Jun |
Date Detail:
|
Created Date: 2007-08-08 Completed Date: 2007-09-06 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0373125 Medline TA: Br J Radiol Country: England |
Other Details:
|
Languages: eng Pagination: 437-45 Citation Subset: AIM; IM |
Affiliation:
|
Department of Diagnostic Radiology, Eberhard-Karls-University Tuebingen, Hoppe-Seyler- Strasse 3, 72076 Tuebingen, Germany. christina.pfannenberg@med.uni-tuebingen.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Aged, 80 and over Clinical Protocols Female Fluorodeoxyglucose F18 / diagnostic use Humans Image Enhancement / methods Image Processing, Computer-Assisted / methods Imaging, Three-Dimensional / methods Male Middle Aged Neoplasms / radiography*, radionuclide imaging* Positron-Emission Tomography / methods* Radiopharmaceuticals / diagnostic use Retrospective Studies Tomography, X-Ray Computed / methods* |
| Chemical | |
Reg. No./Substance:
|
0/Radiopharmaceuticals; 63503-12-8/Fluorodeoxyglucose F18 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Analysis of diagnostic confidence and diagnostic accuracy: a unified framework.
Next Document: MR monitoring of cyclooxygenase-2 inhibition of angiogenesis in a human breast cancer model in rats.